Home > Inhibitors & Agonists
Cat. No. Product name CAS No.
DCC1792 Dihydromotuporamine C Trihydrochloride

Unique antimigration and antiangiogenic agent

855997-15-8
DCC1793 Diic16tac

Novel lipid-based, high-density, environmentally sensitive (HIDE) probe

DCC1794 Diic16'tco

Novel lipid-based, high-density, environmentally sensitive (HIDE) probe

DCC1795 Dilazep

Vasodilator for the treatment of cardiopathy and renal disorders, acting as an adenosine reuptake inhibitor.

35898-87-4
DCC1796 Dimenthyl (1s,2s)-cyclopropane-1,2-dicarboxylate

Building Block

96149-00-7
DCC1797 Dimenthyl Succinate

Building Block

34212-59-4
DCC1798 dimethacrine

Novel inhibitor of AMA1-RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Antidepressant; Acetylcholinesterase inhibitor

4757-55-5
DCC1799 Dimethothiazine

Serotonin antagonist and histamine antagonist

7456-24-8
DCC1800 Dimethoxy-etomidate

Novel analog of etomidate, potently inhibiting 11-beta-hydroxylase without GABAA receptor positive modulatory and sedative-hypnotic activities

DCC1801 Diminazene

Anti-infective agent against certain protozoa such as Babesia, Trypanosoma, Cytauxzoon, and certain bacteria including Brucella and Streptococcus

536-71-0
DCC1802 Dimiq Hydrochloride

Inhibitor of Topoisomerase>DNA topoisomerase II; very potent cytotoxic antitumor agent

1011460-73-3
DCC1803 Dinalbuphine Sebacate

Long-lasting prodrug of nalbuphine, acting as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor and as a high-efficacy partial agonist of the κ-opioid receptor

311768-81-7
DCC1804 Dinapsoline

Natural full D1 dopamine receptor agonist

458563-40-1
DCC1805 Dipicrylamine Sodium Salt

Potent antagonist of GABA A receptors that contain alpha1 and beta2 subunits

13474-21-0
DCC1806 Dipquo

Novel activator of the bone marker alkaline phosphatase (ALP), markedly promoting osteoblast differentiation, including expression of Runx2, Osterix, and Osteocalcin, mediating osteogenesis through activation of p38-β

1269365-82-3
DCC1807 Dipraglurant

Novel negative allosteric modulator of the mGlu5 receptor

872363-17-2
DCC1808 Displurigen

Inhibitor of ATPase activity of HSP70

96156-26-2
DCC1809 Distamycin A Hydrochloride

Antibiotic, specifically inhibiting the initiation of RNA synthesis, binding isohelically to the minor groove of B-DNA at A/T rich sites

6576-51-8
DCC1810 Distigmine Dibromide

Parasympathomimetic with longer duration of action

15876-67-2
DCC1811 Djt06001

Novel selective Factor Xa inhibitor, reducing thrombus formation with low risk of bleeding

1628182-40-0
DCC1812 Dk-1-150

Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line

DCC1813 Dk-1-166

Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line

2204279-20-7
DCC1814 Dk-139

Inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells

1426059-23-5
DCC1815 Dk-1-49

Novel autophagonizer, inducing autophagic cell death in apoptosis-defective cell line

853136-76-2
DCC1816 Dl0410

Novel acetylcholinesterase inhibitor, promoting synaptic function and neuronal survival, ameliorating cognitive deficits in SAMP8 mice via improved mitochondrial dynamics and increased activity of the NMDAR-CREB-BDNF pathway

DCC1817 D-lana-14

Novel potent anti-MRSA agent, disrupting biofilms with no resistance development, sensitizing rifampicin and tetracycline against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

DCC1818 Dlc27-14

Specific protein disorder catalyzer of HIV-1 Nef

1360869-92-6
DCC1819 Dl-threo-dihydrosphingosine

Competitive inhibitor of both SPHK1 and SPHK2

2304-75-8
DCC1820 D-luciferin Phosphate Sodium Salt

Ultrasensitive bioluminogenic enzyme substrate

145613-12-3
DCC1821 D-lys(z)-pro-arg-pna

Chromogenic peptide substrate, being highly sensitive for the measurement of activated Protein C.

108963-69-5
DCC1822 Dma-cpptl

Prodrug of CPPTL, inducing apoptosis in a dose-dependent manner via the ROS/JNK pathway in acute myeloid leukemia

DCC1823 Dmako-20

Novel multi-target anticancer prodrug activated by the tumor specific CYP1B1 enzyme, potently inhibiting HCT-15, HCT-116 and K562 cells growth, showing moderate anti-proliferative activity towards MDA-MB-231, HepG2, PANC, Bel7402 and MGC803 cancer cells,

DCC1824 Dmako-5

Novel antineoplastic agent, exhibiting remarkable anticancer activity as well as excellent cellular selectivity

DCC1825 D-mannuronic Acid [6906-37-2]

Novel blocker of the TLR2 and TLR4 downstream signaling pathway, effectively inhibiting mRNA expression of MyD88 and p65, major subunit of nuclear factor-kappaB

6906-37-2
DCC1826 Dmb213

Novel non-nucleoside inhibitor of Zika viral RNA-dependent RNA polymerase (RdRp) enzymes

DCC1827 Dmcl1-2

Novel potent and selective PROTAC degrader of myeloid cell leukemia 1 (MCL1)

2351218-88-5
DCC1828 Dmnpe-caged Luciferin

Novel cell permeable caged Luciferin

223920-67-0
DCC1829 Dmocptl

Novel inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells

DCC1830 Dmt-dalda

Potent and highly selective µ opioid agonist

DCC1831 Dmxb-a

Novel,orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor

148372-04-7
DCC1832 Dna Primase Inhibitor-1

Novel DNA primase inhibitor

874787-49-2
DCC1833 Dna Primase Inhibitor-13

Novel DNA primase inhibitor

261363-54-6
DCC1834 Dnac-1

Novel potentiator of β-lactam activity against Gram positive and Gram negative pathogens

1006021-30-2
DCC1835 Dndi-0690

Novel antitubercular and antiparasitic agent, possessing excellent in vitro activity against both L. donovani and Leishmania infantum as well as displaying a better safety profile

DCC1836 Do-601

Analeptic agent, stimulating central nervous system; Anti-barbiturate-overdose

100252-00-4
DCC1837 Dolastatin 10 Featured

Highly potent cytotoxic microtubule inhibitor

110417-88-4
DCC1838 Doot-2d

Selective MAO-B inhibitor

1522345-35-2
DCC1839 Dora 42

Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA)

1030377-48-0
DCC1840 Doramectin

Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle

117704-25-3
DCC1841 Dothiepin Hydrochloride

Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects

25627-36-5
DCC1842 Dov51892

Agonist of GABAA receptors α15 subunits

864673-91-6
DCC1843 Dp-326

Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections

DCC1844 Dpa-154

Novel effective and selective inhibitor of E. coli topoisomerase I

DCC1845 Dpb163-ae

Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum.

DCC1846 Dpbx-l-dopa

Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors

DCC1847 Dp-c-1

Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP

DCC1848 Dpf-p10

First Potent Small Molecule Ligand for MALAT1

DCC1849 Dpi-287

Novel highly selective agonist for the δ-opioid receptor, producing less convulsions than most drugs from this family and having antidepressant-like effects

DCC1850 Dpp7-in-5385

Novel inhibitor of dipeptidyl peptidase 7 (DPP7)

DCC1851 Dpp8/9-in-8j

Novel selective DPP8/9 inhibitor, blocking AML progression in vivo

DCC1852 Dppe Hydrochloride

Substrate of CYP3A and inhibitor of P-glycoprotein

92981-78-7
DCC1853 Dpre1-in-377790

Novel DprE1 inhibitor, killing M. tuberculosis

634167-64-9
DCC1854 D-propargylglycine

Click chemistry tool molecule in probing peptidoglycan (PG)

198774-27-5
DCC1855 Dp-v-4

Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP

DCC1856 Dri-c23041

Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV

DCC1857 Dri-c91005

Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV

DCC1858 Dropropizine

Oral non-opioid anti-tussive agent for treatment of cough

17692-31-8
DCC1859 Drostanolone Propionate

Inhibitor of the growth of estrogen receptor-presenting breast cancers

521-12-0
DCC1860 Ds08210767

Novel potent PTHR1 antagonist

2376334-75-5
DCC1861 Ds19161384

Novel selective PPARγ modulator, resulting in robust plasma glucose reductions with excellent DMPK profiles

DCC1862 Ds28120313

Novel potent orally active hepcidin production inhibitor

2146177-09-3
DCC1863 Ds37571084

Novel and orally bioavailable PTHR1 antagonist

DCC1864 Ds-3801b Hydrochloride

Novel non-macrolide GPR38 agonist

1369414-03-8
DCC1865 Ds42450411

Novel potent orally active hepcidin production inhibitor

DCC1866 Ds79932728

Novel Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease

DCC1867 Dsba Inhibitor F1

Pathogen motility inhibitor of EcDsbA

859833-20-8
DCC1868 Dshs00884

Non-toxic human papillomavirus E6 inhibitor

675104-49-1
DCC1869 Dsm-338

Novel Plasmodium falciparum Dihydroorotate Dehydrogenase (PfDHODH) Inhibitor (Pfalcip cells: 0.0018 μM)

DCC1870 Dsm502 Featured

Novel potent inhibitor of dihydroorotate dehydrogenase (DHODH)

2426616-55-7
DCC1871 Dsm705

Novel potent Dihydroorotate Dehydrogenase (DHODH) inhibitor

2653225-38-6
DCC1872 Dsr-98776

Novel selective mGlu5 receptor negative allosteric modulator (NAM) with potent antidepressant and antimanic activity

DCC1873 Ds-sg-44

Agonist of S1P receptors

DCC1874 Dt-061

Novel potent and orally active activator of PP2A

1809427-19-7
DCC1875 Dt2216nc

Negative control for DT2216

DCC1876 Dtagv-1

Potent and selective degrader of mutant FKBP12F36V fusion proteins

DCC1877 Du-34569 Maleate

Antiviral agent against influenza A, parainfluenza Sendai, coxsackie A21, and rhinovirus

34522-38-8
DCC1878 Duocarmycin A

Irreversible DNA minor groove binding alkylating agent, disrupting the nucleic acid architecture and leading to tumor cell death

118292-34-5
DCC1879 Dutomycin

Anthracycline antibiotic from Streptomyces

146663-67-4
DCC1880 Dv-7028

Selective 5-HT2A receptor antagonist

133364-63-3
DCC1881 Dv-7028 Hydrochloride

Potent and selective 5-HT 2A receptor antagonist

133364-62-2
DCC1882 Dw10075

Novel potent and highly selective inhibitor of VEGFR, exhibiting antitumor activities both in vitro and in vivo.

1804982-31-7
DCC1883 Dw-1350

Novel and potent leukotriene B(4) receptor antagonist

491577-61-8
DCC1884 Dwn-723-23

Novel Hsp70 agonist, showing no cellular toxicity and induced cellular stress response pathways

DCC1885 Dx2-hsp70 Inhibitor-1

Novel allosteric inhibitor of the tumor-promoting interaction between the oncogenic factor AIMP2-DX2 and HSP70

125105-17-1
DCC1886 Dx-52-1

Antitumor antibiotic

96251-59-1
DCC1887 Dy3002

Novel Selective and Potent EGFR Inhibitor, Overcoming T790M-Mediated Resistance in Non-Small Cell Lung Cancer

2020015-37-4
DCC1888 Dy428174

Novel potent Inhibitor of PI3Kalpha

1202041-71-1
DCC1889 E09241

Novel OPG/RANKL upregulator, increasing OPG expression without affecting RANKL expression, promoting osteoblast differentiation while inhibiting osteoclast differentiation, regulating OPG expression through canonical Wnt/β-catenin signaling

1043110-13-9
DCC1890 e2012-bpyne

γ-Secretase modulator (GSM) photoaffinity probe, revealing distinct allosteric binding sites on presenilin

1430800-80-8
DCC1891 E235-1756

Potent Activator of P53-Independent Cellular Senescence

891894-69-2
DCC1892 E3-ligase Degrader 10

Novel XIAP BIR2 domain-binding degrader of E3 ubiquitin ligases

DCC1893 E-5842 Citrate

Sigma1 receptor ligand and potential atypical antipsychotic

220120-14-9
DCC1894 Ea-b3a

Novel degrader of GST-α and GST-α-EGFP fusion proteins as well as endogenous GST-π in cells and lysates

DCC1895 Ebi-13a

Highly potent and selective activator of isozymes CA-VA and CA-VII

147596-31-4
DCC1896 Ebmi-13b

Highly potent and selective activator of isozymes CA-VA and CA-VII

21202-53-9
DCC1897 Ebopiprant

Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist

2005486-31-5
DCC1898 Ebov-in-c31

Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties

752216-12-9
DCC1899 Ebselen Oxide

Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis

104473-83-8
DCC1900 Ebv Activator C60

Novel EBV activator, well-performing EBV lytic cycle inducer

1031658-01-1
DCC1901 Ecdsbb-in-12

Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme

112749-52-7
DCC1902 Ecdsbb-in-9

Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria

41933-33-9
DCC1903 Echinoside A

Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle

75410-53-6
DCC1904 Ecraprost

Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders

136892-64-3
DCC1905 Edoxaban Isomer

An impurity of Edoxaban, a novel inhibitor of factor Xa

1255529-24-8
DCC1906 Eef2k-in-21i

Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways

DCC1907 Efatutazone

Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity

223132-37-4
DCC1908 Efonidipine

Calcium channel blocker, blocking both T-type and L-type calcium channels

111011-63-3
DCC1909 Efrapeptin F

Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo

131353-66-7
DCC1910 Efrotomycin

Antibiotic, inhibiting bacterial protein synthesis

56592-32-6
DCC1911 Egfr T790m Inhibitor 6a

Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer

DCC1912 Egfr-in-451

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

220576-72-7
DCC1913 Egfr-in-542

Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications

1639040-81-5
DCC1914 Egfr-in-557

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

1639040-91-7
DCC1915 Egis-11150

Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors.

494861-87-9
DCC1916 Egis-8332

Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination

220725-87-1
DCC1917 Egonol

Antibacterial agent

530-22-3
DCC1918 Eh-201

Arginase Inhibitor, activating EPO-mediated mitochondrial function and haemoglobin expression, stimulating melanogenesis by MAP kinase activation and tyrosinase upregulation

55327-45-2
DCC1919 Ehi1471

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

DCC1920 Ehi2119

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

DCC1921 Ehi2225

Potent and bio-stable inhibitor of the chicken sEH (chxEH)

DCC1922 Eht5372

Novel Mirk kinase inhibitor, inhibiting DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites, blocking the in vivo growth of pancreatic cancer cells

1425945-60-3
DCC1923 Eidd-1619

Novel water-soluble analog of progesterone

1659302-92-7
DCC1924 Eidd-1723

Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity

1659302-89-2
DCC1925 Eif4a Inhibitor 28

Novel RNA-competitive, ATP-uncompetitive eIF4A Inhibitor, decreasing BJAB Burkitt lymphoma cell viability, engaging a novel pocket in the RNA groove of eIF4A and inhibiting unwinding activity by interfering with proper RNA binding and suppressing ATP hydr

DCC1926 Ejmch-6

Novel anti-bacterial agent, targeting the MmpL3 transporter in Mycobacterium abscessus

DCC1927 Ejr-866-75

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

DCC1928 Ejr-866-81

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

DCC1929 El-0052

Novel etomidate analogue, enhancing GABA A receptors currents with a concentration for 50% of maximal effect (EC 50 ) of 0.98 {plus minus} 0.02 μM, which was about three times more potent than etomidate (3.07 {plus minus} 1.67 μM), retaining the favorable

DCC1930 El-228

Novel inhibitor of Aurora B kinase

DCC1931 Ela23-32

Novel ligand of the apelin receptor (APJ), possessing high affinity for APJ (Ki 4.6 nM) and producing cardiorenal effects in vivo similar to those of ELA

DCC1932 elaidyl-sulfamide

Oleoylethanolamide-modelled PPAR

945009-57-4
DCC1933 Elnd006

Novel γ-secretase inhibitor

959997-22-9
DCC1934 Elovl1 Inhibitor 22

Novel highly potent, selective, and CNS-penetrant inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme

DCC1935 Elx-02

Eukaryotic Ribosomal Selective Glycoside (ERSG), inducing read-through of premature stop codons (PSCs) and resulting in translation of full-length protein

1375073-95-2
DCC1936 Em20-25

Novel BCL-2 inhibitor, neutralizing the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitizing BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine

141266-44-6
DCC1937 em-800

High affinity ligand for estrogen receptor-

182167-03-9
DCC1938 Emac4001

Novel potent antitumor agent, inducing apoptosis in a panel of tumor cell lines

DCC1939 Emd-1204831

Novel potent and highly selective c-Met inhibitor

1362819-72-4
DCC1940 Emd57439

PDE 3 inhibitor

148714-88-9
DCC1941 Emd-66684

Non-peptide angiotensin II receptor antagonist

187683-79-0
DCC1942 Emdb-1

Novel peptide endomorphin (EM) degradation blocker

DCC1943 Emdb-2

Novel peptide endomorphin (EM) degradation blocker

DCC1944 Emdb-3

Novel peptide endomorphin (EM) degradation blocker

DCC1945 Emicerfont

Novel corticotropin-release factor 1 antagonist

786701-13-1
DCC1946 Emitefur

5-FU derivative, with various anticancer agents against human cancer xenografts

110690-43-2
DCC1947 Eml108

Novel PRMT inhibitor, preventing arginine methylation of cellular proteins, being essentially inactive against the lysine methyltransferase SET7/9

DCC1948 Eml981

Novel Potent and Selective Inhibitor of Protein Arginine Methyltransferase 4 (PRMT4)

DCC1949 Emoxypine Succinate

Antioxidant, inhibiting free radical oxidation of biomembrane lipids, modulating the activity of membrane-bound enzymes and the receptor complexes of the brain membranes

127464-43-1
DCC1950 En3356

Novel non-steroidal CYP17 inhibitor. reducing androgen synthesis for treatment of castration-resistant prostate cancer

1429329-63-4
DCC1951 Ena739155

Novel butyrylcholinesterase inhibitor against Alzheimer's disease

DCC1952 Encenicline

Novel Potentiator of α7 Receptor Signaling

550999-75-2
DCC1953 Endo-3-aminotropane Dihydrochloride

Useful pharmceutical building block

5424-16-8
DCC1954 Endochin

Antimalarial

354155-51-4
DCC1955 Endosidin1

Natural vesicle trafficking inhibitor

57672-91-0
DCC1956 Endosidin3

Specific inhibitor of trafficking pathways, disrupting recycling at the PM via interference with ROP6/RIC1 signalling

DCC1957 Endosidin4

Novel inhibitor of eukaryotic ARF-GEFs (ADP-ribosylation factor guanine nucleotide exchange factors)

DCC1959 Endosidin7

Specific inhibitor for plant callose deposition during cytokinesis without affectting endomembrane trafficking during interphase or cytoskeletal organization

329072-88-0
DCC1960 Endosidin8.0

Novel modulator of the PIN1 accumulation, selectively modifying PIN1 basal plasma membrane targeting in Arabidopsis with minimal effects on apical plasma membrane proteins

444286-45-7
DCC1961 Endosidin8.1

Novel modulator of the PIN1 accumulation, selectively modifying PIN1 basal plasma membrane targeting in Arabidopsis with minimal effects on apical plasma membrane proteins

DCC1962 Eniporide Hydrochloride

Sodium/hydrogen exchange inhibitor

211813-86-4
DCC1963 Enl-in-7

Novel potent inhibitor of eleven-nineteen leukemia (ENL) protein, selectively targeting the ENL YEATS domain

DCC1964 Enmd-2076 Tartrate

Novel oral inhibitor of angiogenic and proliferation kinases, having activity in recurrent, platinum resistant ovarian cancer

1291074-87-7
DCC1965 Enpp1 Inhibitor 43

Novel potent inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1 or NPP1), showing good in vitro potency, stability in SGF/SIF/PBS, selectivity, ADME properties and pharmacokinetic profile and finally potent anti-tumor response in viv

DCC1966 Enprostil

PGE2 analog, inhibiting gastric acid secretion

73121-56-9
DCC1967 Ent Naxagolide Hydrochloride

Dopamine D2-receptor agonist for the treatment of extrapyramidal disorders, also being an antiparkinson agent

100935-99-7
DCC1968 Entasobulin Featured

Entasobulin is a β-tubulin polymerization inhibitor with potential anticancer activity.

501921-61-5
DCC1969 Entpd5-in-1a

Novel inhibitor of Ectonucleoside Triphosphate Diphosphohydrolase 5 (ENTPD5)

DCC1970 Entpd5-in-2f

Novel inhibitor of Ectonucleoside Triphosphate Diphosphohydrolase 5 (ENTPD5)

DCC1971 Ent-verticilide

Unnatural verticilide enantiomer, inhibiting type 2 ryanodine receptor-mediated calcium leak and being antiarrhythmic.

DCC1972 Ep-7041

Novel, potent, and selective Factor XIa inhibitor

1803271-50-2
DCC1973 Epc-k1

Vitamin E derivative, suppressing inflammation during hepatic ischemia-reperfusion injury and exerting hepatoprotective effects

127061-56-7
DCC1974 Epetraborole R-mandelate

Novel potent and selective leucyl-tRNA synthetase inhibitor

1234563-15-5
DCC1975 Epha2-agonist-27

Novel agonist of EphA2 receptor tyrosine kinase

DCC1976 Ephb1-in-10

Potent and selective covalent inhibitor of receptor tyrosine kinase EphB1

DCC1977 Ephb3-in-10

Novel clickable potent and specific inhibitor of EphB3

DCC1978 Ephb3-in-9

The first potent and specific inhibitor of a single Eph isoform EphB3

DCC1979 Epi-0023

Novel selrctive SETD8 inhibitor without inhibiting G9a, SETD7, RmtA, and PRMT1

3963-80-2
DCC1980 Epibestatin Hydrochloride

Novel stabilizer of 14-3-3 PPIs, Diastereoepimer of aminopeptidase inhibitor bestatin

100992-60-7
DCC1981 Epinastine Hydrobromide

Second-generation antihistamine and mast cell stabilizer, being highly selective for the H1 receptor

127786-29-2
DCC1982 Epi-nocardicin G

The precursor of the nocardicins

DCC1983 Eprazinone

Mucolytic and bronchospasm relieving agent

10402-90-1
DCC1984 Eps-in-1

Novel inhibitor of extracellular polymeric substances (EPS)

DCC1985 Eptapirone Fumarate

Potent, selective, high efficacy 5-HT1A receptor agonist

179756-85-5
DCC1986 Epz005687n

Inactive isomer of EPZ005687 and can be used as the negative control for EPZ005687

DCC1987 Epz028862

Novel selective SMYD3 inhibitor

DCC1988 Epz032597

Novel selective SMYD2 inhibitor

DCC1989 Epz033294

Novel SMYD2 inhibitor

DCC1990 Er Degrader 40

Novel Oral Selective Estrogen Receptor Degrader with Highly Improved Antitumor Effect and Favorable Druggability

DCC1991 Er-119884

Selective squalene synthase (SQS) inhibitor

DCC1992 Er-38925

Retinoic acid receptor (RAR) subtype α-selective agonist

196517-43-8
<Prev1...161162163164165...191Next>